newsfilter
← Latest News
GlobeNewswire·

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

ATHE
  • USPTO granted a new composition of matter patent for ATH434, Alterity Therapeutics' lead clinical asset.
  • The patent provides protection for a crystalline structure of the mesylate salt form of ATH434 & methods for treating neurological conditions.
  • Patent protection extends for ATH434 to at least 2045, significantly enhancing its commercial potential.
  • The crystalline form covered by the patent was used in Phase 2 trials & will be utilized in the planned Phase 3 study for Multiple System Atrophy (MSA).
  • Alterity plans to initiate Phase 3 trial activities for MSA by year-end 2026.
  • The new intellectual property enables future development of ATH434 for Parkinson's disease & other major neurodegenerative disorders.
  • ATH434 is an oral agent designed to reduce iron accumulation & inhibit abnormal protein aggregation in neurodegenerative diseases.
  • ATH434 holds Fast Track Designation & Orphan Drug Designation from the FDA & European Commission for MSA treatment.
  • Positive results were reported from Phase 2 clinical trials in MSA patients, demonstrating efficacy, target engagement, & a favorable safety profile.
  • The patent is expected to be listed in the FDA's Orange Book upon regulatory approval of ATH434 for commercialization.